Interleukin-23

Healio spoke with Philip J. Mease, MD, about recent advancements in psoriatic arthritis.

SCOTTSDALE, Ariz. — Understanding patients’ disease burden and priorities can help rheumatologists choose the best therapy for psoriatic arthritis, noted a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.

Risankizumab appeared to worsen severe asthma symptoms compared with placebo, according to results of a randomized phase 2a study published in The New England Journal of Medicine.

Risankizumab is linked to significantly greater improvements in psoriatic arthritis signs and symptoms than placebo in patients with an inadequate response, or intolerance, to other drugs, according to a speaker at the EULAR 2021 Congress.

Although a range of biologic options are available to clinicians treating psoriatic arthritis, it crucial to know which disease domains are involved as this will “dictate treatment,” according to a presenter at the Biologic Therapies Summit.

Treatment with bimekizumab, an interleukin-17A and IL-17F inhibitor in adults with chronic plaque psoriasis, resulted in at least a 90% improvement in the Psoriasis Area and Severity Index and Investigator Global Assessment score of clear or almost clear, according to phase 3 results from the development program BE VIVID by UCB.

The safety and efficacy of Ilumya were maintained after 4 years of treatment among patients with plaque psoriasis enrolled in the open-label reSURFACE1 trial, according to data presented at the European Academy of Dermatology and Venereology Congress.

A significantly greater proportion of patients with psoriasis receiving guselkumab achieved a 90% reduction or more in the Psoriasis Area and Severity Index at week 48 than those receiving secukinumab, according to researchers in The Lancet.